Expert Interview
Discussing the recent phase 2 data of barzolvolimab in two of the most common forms of CIndU - Cold Urticaria and symptomatic dermographism
Ticker(s): CLDXInstitution: University of Rochester
- Professor of Dermatology, Professor of Medicine (AIR) and Pathology & Laboratory Medicine at University of Rochester Medical Center.
- Manages 500 patients with atopic dermatitis (60% Pediatric) and 30 patients per month with chronic urticaria.
- Research was instrumental in the development of dupilumab (Dupixent); Lead author of a 2014 NEJM paper that set the stage for the FDA approval of Dupixent.
Roughly how many patients with cold urticaria do you manage annually?
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for barzolvolimab?
Added By: c_adminCan you provide an overview of your clinical practice and research interests, specifically regarding urticaria?
Added By: catalin_adminHow common are induced urticaria cases in your practice, and how do they typically present in comparison to spontaneous urticaria?
What are the etiological differences between chronic spontaneous urticaria and induced urticaria?
What theories do you have about the triggers of chronic urticaria, and how do these impact treatment approaches?
What percentage of your patients with induced urticaria show insufficient response to antihistamines and XOLAIR?
How do you perceive the potential of barzolvolimab compared to omalizumab, especially considering safety profiles and side effects like hair color changes and neutropenia?
What are your thoughts on the efficacy and clinical testing methods used for barzolvolimab, and how do these compare to standard practice?
How do you foresee BTK inhibitors, particularly remibrutinib from Novartis, fitting into the treatment landscape for chronic spontaneous urticaria?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
